A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer
To determine whether [18F]FES can predict clinical benefit (defined as complete response,
partial response and stable disease ≥ 6 months) to fulvestrant (250 mg IM q 28 days) in
post-menopausal women with recurrent or metastatic ER+ breast cancer who are candidates for
further hormonal therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society